Dipraglurant is under clinical development by Addex Therapeutics and currently in Phase II for Blepharospasm. According to GlobalData, Phase II drugs for Blepharospasm have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dipraglurant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dipraglurant overview
Dipraglurant is under development for the treatment of levodopa induced dyskinesia associated with Parkinson's disease (PD-LID), post-stroke recovery, traumatic brain injury (TBI) and blepharospasm. It is administered through oral route and acts by targeting mGluR5. The drug candidate is being developed based on allosteric modulator discovery technology platform. It is a negative allosteric modulator or NAM.
The drug candidate was under development for the treatment of dystonia, treatment resistant depression, addiction, anxiety disorders, Huntington disease, Lewy body dementia, obsessive-compulsive disorder and pain.
Addex Therapeutics overview
Addex Therapeutics (Addex) is a clinical-stage pharmaceutical company primarily engaged in the development of novel orally available small molecule drug candidates. The company’s portfolio includes a pipeline of proprietary clinical and preclinical stage drug candidates, developed both internally and in collaboration with partners. Addex’s lead drug candidates include ADX71149, developed in partnership with Janssen Pharmaceuticals for the treatment of epilepsy, and dipraglurant, a wholly owned drug candidate under evaluation for Parkinson’s disease levodopa induced dyskinesia (PD-LID) and post-stroke/TBI recovery. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. The company’s drug candidates are designed to address epilepsy, Parkinson’s disease, post-stroke sensorimotor recovery, traumatic brain injury, substance use disorder, and cough. Addex’s products are primarily targeted towards the healthcare and pharmaceutical industries. The company collaborates with various partners, including Janssen Pharmaceuticals and Indivior PLC, for the development and commercialization of its drug candidates. Addex is headquartered in Geneva, Switzerland.
For a complete picture of Dipraglurant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
